FORMA Therapeutics将在2019年肝脏会议®上展示FASN抑制剂FT-4101的数

StephenW

FORMA Therapeutics to Present Data for FASN Inhibitor FT-4101 at The Liver Meeting® 2019
October 01, 2019 04:05 PM Eastern Daylight Time

WATERTOWN, Mass.--(BUSINESS WIRE)--FORMA Therapeutics, Inc. today announced that new data related to FT-4101, its novel, small molecule fatty acid synthase (FASN) inhibitor, in clinical development for the treatment of nonalcoholic steatohepatitis (NASH), will be presented at The Liver Meeting® 2019, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) taking place November 8-12, 2019 in Boston, MA.

    “Inhibition of fatty acid synthase (FASN) with FT-4101 reduces hepatic de novo lipogenesis (DNL) in healthy adult subjects”
    Tweet this

“Inhibition of fatty acid synthase (FASN) with FT-4101 reduces hepatic de novo lipogenesis (DNL) in healthy adult subjects” (#2151) will be presented in a poster session in Hall B of the Hynes Convention Center at the following times:

Friday, November 8: 8:00 am – 5:30 pm; Presenters Available: 12:30 – 1:30pm
Saturday, November 9: 2:00 pm–7:00 pm; Presenters Available: 5:15 – 6:15pm
Sunday, November 10: 8:00 am – 5:30 pm; Presenters Available: 12:30 – 1:30pm
Monday, November 11: 8:00 am – 5:30 pm; Presenters Available: 12:30 – 1:30pm

The full abstract can now be accessed through the AASLD website, https://aasld.org/education/learn-person/liver-meeting/abstracts

About FT-4101

FT-4101 is a potent, selective, oral small molecule inhibitor of fatty acid synthase (FASN) expected to reduce the rate of new fat production or de novo lipogenesis, thereby systemically affecting lipid accumulation in the liver and potentially mitigating the cellular damage, inflammation, and fibrosis that characterizes the pathology of nonalcoholic steatohepatitis (NASH). It is estimated that 3-12% of adults in the United States have NASH. A clinical study evaluating FT-4101 in adult subjects with NASH is ongoing.

FORMA is also evaluating a pre-clinical, next generation, liver-targeted potent inhibitor of FASN, FT-8225, expected to have unique distribution.

About FORMA

FORMA Therapeutics is a privately-held, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of transformative medicines that will make a difference for patients in need. A fully-integrated biopharmaceutical company, FORMA’s validated, proprietary R&D engine combines deep biology insight, chemistry expertise and clinical development capabilities to create differentiated drug candidates with best-in-class or first-in-class potential. FORMA has delivered high-value clinical candidates to its partners and generated a broad proprietary portfolio of programs, ranging from pre-clinical to pivotal-stage, with the potential to provide profound patient benefit in hematologic, oncologic, and metabolic indications. For more information, please visit the company website at www.formatherapeutics.com.

StephenW

FORMA Therapeutics将在2019年肝脏会议®上展示FASN抑制剂FT-4101的数据
十月01，2019 04:05 PM东部夏令时间

马萨诸塞州沃特敦-（BUSINESS WIRE）-（美国商业资讯）-FORMA Therapeutics，Inc.今天宣布，与FT-4101（其新型的小分子脂肪酸合酶（FASN）抑制剂）相关的新数据正在用于非酒精性脂肪性肝炎的临床开发中（NASH）将在2019年肝脏会议（美国肝脏疾病研究协会（AASLD）年会）上发表，该会议将于2019年11月8日至12日在马萨诸塞州波士顿举行。

    “用FT-4101抑制脂肪酸合酶（FASN）可减少健康成人受试者的肝脏新生脂肪形成（DNL）”
    推特

“用FT-4101抑制脂肪酸合酶（FASN）可减少健康成人受试者的肝新生脂肪形成（DNL）”（＃2151）将在以下时间在海因斯会议中心B厅的张贴会议上介绍：

11月8日，星期五：上午8:00 –下午5:30；发言人可用：12:30 – 1:30 pm
11月9日，星期六：2：00 pm – 7:00 pm；发言人可用：下午5:15 – 6:15
11月10日，星期日：上午8:00 –下午5:30；发言人可用：12:30 – 1:30 pm
11月11日，星期一：上午8:00 –下午5:30；发言人可用：12:30 – 1:30 pm

现在可以通过AASLD网站https://aasld.org/education/learn-person/liver-meeting/abstracts访问完整的摘要

关于FT-4101

FT-4101是一种有效的，选择性的，口服的脂肪酸合酶小分子抑制剂，有望降低新脂肪的产生或从头开始脂肪形成的速率，从而系统性地影响肝脏中脂质的蓄积并可能减轻细胞损伤，炎症以及以非酒精性脂肪性肝炎（NASH）病理为特征的纤维化。据估计，美国有3-12％的成年人患有NASH。一项正在进行的评估FT-4101在成人NASH患者中的临床研究正在进行中。

FORMA还正在评估FASN的临床前，下一代，肝靶向的强效抑制剂FT-8225，预计其具有独特的分布。

关于FORMA

FORMA Therapeutics是一家私有的临床阶段生物制药公司，致力于发现，开发和商业化转化药物，这些药物将为有需要的患者带来改变。 FORMA经过验证的专有研发引擎是一家完全集成的生物制药公司，结合了深厚的生物学洞察力，化学专业知识和临床开发能力，可以创建具有一流或一流潜力的差异化候选药物。 FORMA已为其合作伙伴提供了高价值的临床候选药物，并产生了广泛的专有项目组合，从临床前阶段到关键阶段，都有可能在血液，肿瘤和代谢适应症方面为患者带来深远的益处。有关更多信息，请访问公司网站www.formatherapeutics.com。